{
}
Alzheimer’s drug development is gaining investor attention, with Biogen's Leqembi and Eli Lilly's Kisunla leading the market despite their limitations in reversing the disease. Novo Nordisk is exploring semaglutide's potential benefits for early Alzheimer’s patients, while Roche and UCB are assessing new treatments amid mixed trial results. The landscape is dynamic, with significant opportunities for firms that can deliver effective therapies.
Merck & Co. has acquired worldwide rights to LaNova Medicines' cancer therapy LM-299 for $588 million, a bispecific immunotherapy targeting PD-1 and VEGF, currently in Phase 1 testing. This move comes as a response to increasing competition, particularly after ivonescimab outperformed Keytruda in a lung cancer trial. The deal could yield LaNova up to $2.7 billion based on development milestones, highlighting Merck's strategy to bolster its pipeline ahead of Keytruda's patent expiration in 2028.
Roche is considering seeking accelerated U.S. approval for its Alzheimer’s drug trontinemab, which shows promise in significantly lowering amyloid protein levels linked to cognitive decline. Early Phase 2 data indicates it may clear amyloid more quickly than competitors, with fewer side effects like ARIA. The company plans to expand its trial to 120 participants while adjusting safety criteria after a related incident.
Eli Lilly's stock plummeted nearly 10% in premarket trading after the company reported Q3 earnings that fell short of Wall Street expectations, with revenue at $11.4 billion against estimates of $12.17 billion. Despite a 20% year-over-year increase, the company cut its profit guidance and revenue outlook, citing inventory decreases impacting sales of its weight-loss drug Zepbound and diabetes drug Mounjaro. The combined sales from these drugs reached $4.4 billion, but Zepbound's revenue missed analyst estimates, raising concerns about the stock's future in a complex healthcare market.
Biogen reported third-quarter revenue of $2.47 billion and adjusted earnings of $4.08 per share, surpassing analyst expectations. The company raised its full-year profit guidance, driven by the growing sales of its Alzheimer's drug, Leqembi, which generated $67 million in the quarter. Despite a year-over-year revenue decline in multiple sclerosis products, the uptake of Leqembi and new treatments for rare diseases and depression helped offset losses.
AbbVie has agreed to acquire Aliada Therapeutics for $1.4 billion, gaining access to innovative drug delivery technology aimed at overcoming the blood-brain barrier and a clinical-stage Alzheimer’s treatment, ALIA-1758. This move aligns with AbbVie’s focus on neuroscience, enhancing its capabilities in developing therapies for neurological disorders. The deal is expected to close by year-end and reflects a strategic investment in a sector facing challenges but also potential breakthroughs.
Eisai Co., Ltd.
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
alzheimer's drug developments signal potential investment opportunities in 2025
Euro
United States Dollar
Novo Nordisk A/S
Eisai Co., Ltd.
Eli Lilly and Co
BioArctic AB
Hoffmann-La Roche AG
UCB SA
AXA Investment Managers SA
BIOGEN
BEL
JPN
USA
SWE
Gregoire Biollaz
Colin White
Sachin Jain
Jean Rivera Irizarry
Chris Eccleshall
Emily Field
Stacy Kubicek
Show more
18:36 10.01.2025
merck invests in new cancer immunotherapy to counter keytruda competition
United States Dollar
LaNova Medicines
Merck & Co., Inc.
Summit Therapeutics plc
Biotheus
Eisai Co., Ltd.
BioNTech SE
Akeso, Inc.
USA
CHN
Umer Raffat
Dean Li
Show more
01:00 14.11.2024
Roche considers accelerated approval for promising Alzheimer’s drug trontinemab
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Hoffmann-La Roche AG
CHE
Eli Lilly
Hanno Svoboda
Biogen
Eisai
Show more
22:44 31.10.2024
eli lilly shares drop after disappointing third quarter earnings report
United States Dollar
Biogen Inc.
Eisai Co., Ltd.
Eli Lilly and Company
USA
Leqembi
Jared Holz
Biogen
Show more
12:18 30.10.2024
biogen exceeds earnings expectations and raises profit outlook amid leqembi sales growth
11:50 30.10.2024
abbvie acquires aliada therapeutics for 1.4 billion to enhance neuroscience portfolio
United States Dollar
Landos Biopharma Inc.
Hoffmann-La Roche AG
Johnson & Johnson
Bristol-Myers Squibb Company
Biogen Inc.
AbbVie Inc.
Cerevel Therapeutics Holdings Inc.
Denali Therapeutics Inc.
Celsius Therapeutics
ImmunoGen Inc.
Eisai Co., Ltd.
USA
Roopal Thakkar
Paul Matteis
Show more
17:05 28.10.2024
Trending
Subcategory
Industry Trends
Corporate News
Supply Chain Management
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Industry Mergers & Acquisitions
Retail and Consumer Goods
Finance Mergers & Acquisitions
Financial Scams and Security
Fintech Startups
Emerging Startups
Workplace Trends
Venture Capital Investments
Cryptocurrency Trends
Funding Rounds & Investments
Energy Sector Developments
CEO Changes
Market Analysis and Predictions
Stock Market Updates
Countries:
Companies:
Apple Inc.
Google Inc.
NVIDIA Corporation
Delhivery Limited
Ecom Express Ltd.
Alphabet Inc.
OpenAI ERC USD
Ciscom Corp.
ERICSSON - CLASS B
Physicswallah Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
Snap Inc.
Tiktok USD
Semiconductor Manufacturing International Corporation
Hua Hong Semiconductor Ltd.
Spotify Technology S.A.
Dropbox, Inc.
Vimeo, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Vietnamese Đồng
New Taiwan Dollar
United Arab Emirates Dirham
Russian Ruble
South Korean Won
Pakistani Rupee
Algerian Dinar
Australian Dollar
Thai Baht
Japanese Yen
Saudi Riyal
People:
Donald Trump
Ilya Sutskever
Peter Thiel
Amal El Fallah Seghrouchni
Trixie Lohmirmand
Scott Bessent
Jamieson Greer
Joe Jurken
Stephen Roachford
David French
Rick Woldenberg
Marc Rosenberg
Isaac Larian
Hichem Djouhri
Laurina Emmanuel
Tim Cook
Andrew Ferguson
Sheryl Sandberg
Mark Zuckerberg
Pavel Prass